201 related articles for article (PubMed ID: 19584719)
1. Molecular markers of aggressiveness of thyroid cancer.
Ringel MD
Curr Opin Endocrinol Diabetes Obes; 2009 Oct; 16(5):361-6. PubMed ID: 19584719
[TBL] [Abstract][Full Text] [Related]
2. New, clinically relevant molecular characterizations of thyroid cancer.
Davis PJ
Curr Opin Endocrinol Diabetes Obes; 2009 Oct; 16(5):359-60. PubMed ID: 19654539
[No Abstract] [Full Text] [Related]
3. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.
Montero-Conde C; Martín-Campos JM; Lerma E; Gimenez G; Martínez-Guitarte JL; Combalía N; Montaner D; Matías-Guiu X; Dopazo J; de Leiva A; Robledo M; Mauricio D
Oncogene; 2008 Mar; 27(11):1554-61. PubMed ID: 17873908
[TBL] [Abstract][Full Text] [Related]
4. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers].
Kazubskaia TP; Kozlova VM; Kondrat'eva TT; Pavlovskaia AI; Marakhonov AV; Baranova AV; Ivanova NI; Stepanova AA; Poliakov AV; Belev NF; Brzhezovskiĭ VZh
Arkh Patol; 2014; 76(5):3-12. PubMed ID: 25543402
[TBL] [Abstract][Full Text] [Related]
5. Encapsulated papillary oncocytic neoplasms of the thyroid: morphologic, immunohistochemical, and molecular analysis of 18 cases.
Woodford RL; Nikiforov YE; Hunt JL; Bellizzi AM; Zhang X; Mills SE; Stelow EB
Am J Surg Pathol; 2010 Nov; 34(11):1582-90. PubMed ID: 20924280
[TBL] [Abstract][Full Text] [Related]
6. The prognostic implications from molecular testing of thyroid cancer.
Ozgursoy OB; Eisele DW; Tufano RP
Otolaryngol Clin North Am; 2014 Aug; 47(4):595-607. PubMed ID: 25041960
[TBL] [Abstract][Full Text] [Related]
7. ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW.
Nikiforov YE
Endocr Pract; 2017 Aug; 23(8):979-988. PubMed ID: 28534687
[TBL] [Abstract][Full Text] [Related]
8. Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy.
Fontaine JF; Mirebeau-Prunier D; Franc B; Triau S; Rodien P; Houlgatte R; Malthièry Y; Savagner F
Oncogene; 2008 Apr; 27(15):2228-36. PubMed ID: 17968324
[TBL] [Abstract][Full Text] [Related]
9. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
[TBL] [Abstract][Full Text] [Related]
10. [Molecular biomarkers involved in the tumor dedifferentiation process of thyroid carcinoma of epithelial origin: perspectives].
González Blanco C; Mato Matute E; de Leiva Hidalgo A
Endocrinol Nutr; 2012; 59(7):452-8. PubMed ID: 22365643
[TBL] [Abstract][Full Text] [Related]
11. Comparison with published systems of a new staging system for papillary and follicular thyroid carcinoma.
Wong RM; Bresee C; Braunstein GD
Thyroid; 2013 May; 23(5):566-74. PubMed ID: 23106409
[TBL] [Abstract][Full Text] [Related]
12. Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array.
Chen KT; Lin JD; Chao TC; Hsueh C; Chang CA; Weng HF; Chan EC
Thyroid; 2001 Jan; 11(1):41-6. PubMed ID: 11272096
[TBL] [Abstract][Full Text] [Related]
13. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density.
Goldenberg JD; Portugal LG; Wenig BL; Ferrer K; Wu JC; Sabnani J
Head Neck; 1998 Mar; 20(2):152-8. PubMed ID: 9484947
[TBL] [Abstract][Full Text] [Related]
14. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
World J Surg; 2006 May; 30(5):767-74. PubMed ID: 16547620
[TBL] [Abstract][Full Text] [Related]
16. Thyroid cancer development and progression: emerging role of cancer stem cells.
Malaguarnera R; Morcavallo A; Giuliano S; Belfiore A
Minerva Endocrinol; 2012 Jun; 37(2):103-15. PubMed ID: 22691885
[TBL] [Abstract][Full Text] [Related]
17. Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma.
Zhao L; Dias-Santagata D; Sadow PM; Faquin WC
Cancer Cytopathol; 2017 May; 125(5):323-331. PubMed ID: 28192645
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA HIT000218960 promotes papillary thyroid cancer oncogenesis and tumor progression by upregulating the expression of high mobility group AT-hook 2 (HMGA2) gene.
Li T; Yang XD; Ye CX; Shen ZL; Yang Y; Wang B; Guo P; Gao ZD; Ye YJ; Jiang KW; Wang S
Cell Cycle; 2017 Jan; 16(2):224-231. PubMed ID: 27929737
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and therapy of differentiated thyroid gland carcinomas].
Mann K
Internist (Berl); 2002 Feb; 43(2):174-85. PubMed ID: 11963755
[No Abstract] [Full Text] [Related]
20. Molecular markers for discrimination of benign and malignant follicular thyroid tumors.
Fryknäs M; Wickenberg-Bolin U; Göransson H; Gustafsson MG; Foukakis T; Lee JJ; Landegren U; Höög A; Larsson C; Grimelius L; Wallin G; Pettersson U; Isaksson A
Tumour Biol; 2006; 27(4):211-20. PubMed ID: 16675914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
